Höflich, Anna
Kraus, Christoph http://orcid.org/0000-0002-7144-2282
Pfeiffer, Ruth M. http://orcid.org/0000-0001-7791-2698
Seiger, Rene http://orcid.org/0000-0003-1556-4346
Rujescu, Dan
Zarate, Carlos A. Jr.
Kasper, Siegfried
Winkler, Dietmar http://orcid.org/0000-0001-8849-9907
Lanzenberger, Rupert http://orcid.org/0000-0003-4641-9539
Funding for this research was provided by:
Intramural Research Program at the National Institute of Mental Health, National Institutes of Health
Oesterreichische Nationalbank (P 14193)
Article History
Received: 26 July 2020
Revised: 17 February 2021
Accepted: 5 March 2021
First Online: 1 April 2021
Conflict of interest
: S. Kasper received grants/research support, consulting fees, and/or honoraria within the last 3 years from Angelini, AOP Orphan Pharmaceuticals AG, AstraZeneca, Eli Lilly, Janssen, KRKA-Pharma, Lundbeck, Neuraxpharm, Pfizer, Pierre Fabre, Schwabe, and Servier. R. Lanzenberger received travel grants and/or conference speaker honoraria within the last 3 years from Bruker BioSpin MR, Heel, and support from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. C. Zarate is a full-time employee of the US government. He is listed as a co-inventor on a patent for the use of ketamine and its metabolites in major depression and suicidal ideation. C. Zarate has assigned his patent rights to the US government but will share a percentage of any royalties that may be received by the government. C. Kraus received support from Janssen, Roche and AOP Orphan. D. Winkler received lecture fees/authorships honoraria within the last 3 years from Angelini, Lundbeck, and Medizin Medien Austria. The remaining authors have no conflicts of interest to declare, financial or otherwise.